+1 212 479 6565 eblanchard@cooley.com
Eric Blanchard advises clients on initial public offerings, follow-on equity offerings, pre-IPO financings, investment-grade, high-yield and convertible debt offerings, liability management transactions, proxy contests and acquisitions. He counsels domestic and foreign public and private companies, with an emphasis on those in the healthcare industry, as well as investment banks. He also regularly represents public companies with securities and disclosure issues and corporate governance matters.
Download full bio
Immunocore $312.1 Million Aggregate Financing
SPAC BowX Agrees to Merger With WeWork
Capital Markets
Public Companies
Emerging Companies
Mergers & Acquisitions
Life Sciences
Technology
He has been absolutely brilliant. He is relaxed, measured, on top of all the issues and a delight to deal with.
Catholic University of America, ColumbusJD, magna cum laude, 1999
University of MarylandBA, 1996
New York
SPAC BowX Agrees to Merger With WeWork March 26, 2021
Immunocore Closes $312.1 Million Aggregate Financing, Makes Public Debut February 23, 2021
SEC Proposes Changes to Rule 701 and Form S‑8 December 1, 2020
View all
+1 212 479 6565 office eblanchard@cooley.com
55 Hudson YardsNew York, NY 10001-2157